23138-58-1

Basic information

• Product Name: 3-ETHYLPHENYL ISOCYANATE
• Synonyms: 3-ETHYLPHENYL ISOCYANATE;Isocyanic acid 3-ethylphenyl ester;1-ethyl-3-isocyanatobenzene(SALTDATA: FREE);Benzene,1-ethyl-3-isocyanato-
• CAS NO: 23138-58-1
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.17
• Product Categories: Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 23138-58-1.mol

Chemical Properties

• Boiling Point: 104 °C40 mm Hg(lit.)
• Flash Point: 185 °F
• Appearance: /
• Density: 1.033 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.15mmHg at 25°C
• Refractive Index: n20/D 1.526(lit.)
• Sensitive: Moisture Sensitive
• BRN: 386718
• CAS DataBase Reference: 3-ETHYLPHENYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ETHYLPHENYL ISOCYANATE(23138-58-1)
• EPA Substance Registry System: 3-ETHYLPHENYL ISOCYANATE(23138-58-1)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 23138-58-1(Hazardous Substances Data)

Usage

Uses

Used in Polymer and Coatings Industry:
3-Ethylphenyl isocyanate is used as a monomer in the synthesis of polymers and coatings, contributing to their enhanced properties such as durability, flexibility, and resistance to environmental factors.
Used in Pharmaceutical Industry:
3-Ethylphenyl isocyanate is used as a key intermediate in the production of pharmaceuticals, enabling the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
3-Ethylphenyl isocyanate is employed as a building block in the synthesis of agrochemicals, such as pesticides and herbicides, to improve their efficacy in controlling pests and weeds while minimizing environmental impact.

InChI:InChI=1/C9H9NO/c1-2-8-4-3-5-9(6-8)10-7-11/h3-6H,2H2,1H3

Upstream product

• 75-44-5 phosgene 
• 587-02-0 m-ethylaniline 

Downstream Products

• 149080-68-2 N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(piperidin-1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-ethylphenyl]urea 
• 1002339-05-0 tert-butyl 4-[(3-ethylphenyl)carbamoyl]-3-(hydroxymethyl)piperazine-1-carboxylate 
• 1202526-39-3 1-(3-ethylphenyl)-3-(2-hydroxy-4-nitrophenyl)urea 
• 1095717-42-2 2-(1,3-benzodioxol-5-yl)-6-{[(3-ethylphenyl)amino]carbonyl}-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl 4-methylbenzenesulfonate 
• 1095715-84-6 2-(1,3-benzodioxol-5-yl)-N-(3-ethylphenyl)-4-(2-methyphenyl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 1095715-85-7 2-(3,5-dimethylisozaxol-4-yl)-N-(3-ethylphenyl)-4-(2-methylphenyl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 1095715-82-4 N-(3-ethylphenyl)-2-(4-fluorophenyl)-4-(2-methylphenyl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 1095717-41-1 2-(1,3-benzodioxol-5-yl)-N-(3-ethylphenyl)-4-hydroxy-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 1610952-35-6 1'-[2-(difluoromethoxy)benzyl]-N-(3-ethylphenyl)-2',5'-dioxospiro[8-azabicyclo[3.2.1]octane-3,4'-imidazolidine]-8-carboxamide 

Relevant articles and documents

Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

Amyloid β (Aβ), a key molecule in the pathogenesis of Alzheimer's disease (AD), is derived from the amyloid precursor protein (APP) by sequential proteolysis via β- and γ-secretases. Because of their role in generation of Aβ, these enzymes have emerged as important therapeutic targets for AD. In the case of γ-secretase, progress has been made towards designing potent inhibitors with suitable pharmacological profiles. Direct γ-secretase inhibitors are being evaluated in clinical trials and new strategies are being explored to block γ-secretase activity indirectly as well. In this regard, we have previously reported an indirect regulation of γ-secretase through antagonism of CXCR2, a G-protein coupled receptor (GPCR). We demonstrated that N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea (SB225002), a selective inhibitor of CXCR2 also plays a role in an indirect inhibition of γ-secretase. Furthermore, we reported a ～5-fold difference in the selective inhibition of APP versus Notch processing via γ-secretase following treatment with SB225002. Herein we describe the synthesis and optimization of SB225002. By determination of the structure-activity relationship (SAR), we derived small molecules that inhibit Aβ40 production with IC50 values in the sub-micromolar range in a cell-based assay and also validated the potential of CXCR2 as a new target for therapeutic intervention in AD.